The role of resveratrol for heterotopic pain caused by orthodontic dental movement

Research Project

Project/Area Number	18K09868
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 57070:Developmental dentistry-related
Research Institution	Azabu University
Principal Investigator	Shimazu Yoshihito 麻布大学, 生命・環境科学部, 准教授 (10297947)
Co-Investigator(Kenkyū-buntansha)	武田守麻布大学, 生命・環境科学部, 教授 (20227036)
Project Period (FY)	2018-04-01 – 2021-03-31
Project Status	Completed (Fiscal Year 2020)
Budget Amount *help	¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000) Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2019: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000) Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Keywords	歯の矯正移動 / ラット / 臼歯 / 疼痛 / 三叉神経節 / ニューロン / グリア細胞 / 免疫組織化学 / 異所性疼痛 / 歯科矯正 / レスベラトロール
Outline of Final Research Achievements	The present study investigated whether administration of resveratrol attenuates the experimental tooth movement (ETM)-induced ectopic hyperalgesia associated with hyperexcitability of SpVc neurons. The threshold of escape from mechanical stimulation applied to the ipsilateral whisker pad in rats exposed to ETM was significantly lower than seen in control rats. The lowered mechanical threshold exposed to ETM had almost returned to the level of sham-treated rats following administration of resveratrol. The mean mechanical threshold of nociceptive SpVc neurons was significantly lower but the lower threshold could be reversed by administration of resveratrol. These results suggest that resveratrol attenuates ETM-induced mechanical ectopic hyperalgesia via suppression of peripheral and/or central sensitization. These findings support the idea that resveratrol is a potential therapeutic agent for the prevention of ETM-induced ectopic hyperalgesia.
Academic Significance and Societal Importance of the Research Achievements	本研究成果として、レスベラトロールは矯正治療時に使用されるNSAIDsに代わり、副作用のない鎮痛薬として使用できる可能性、すなわち補完代替医療に貢献することが示唆された。これに加えて本研究の結果は、矯正処置時の歯の移動による三叉神経支配領域の炎症性痛覚過敏において、レスベラトロールが有効であるということが、歯科の臨床上有用であるインプラントなどの処置後に発生する三叉神経痛等の神経障害性疼痛においても効果が期待できることが推察された。今後、臨床応用を視野に入れた更なる研究が期待される。